Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
about
Oral administration of a retinoic Acid receptor antagonist reversibly inhibits spermatogenesis in miceThe effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (ComPhosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.Roles of prohibitin in growth control and tumor suppression in human cancersBaseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital.Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) SurveyUnderstanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study.Diagnosis and management of benign prostatic hyperplasia in primary care.Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and T
P2860
Q24631865-AFDA9836-73B5-4B30-A1D8-F104670A8A49Q33829176-F7ACA132-A9A0-4B7F-A6FE-9C0BEAA1D514Q33953840-D4C46412-359B-4011-8F43-9E66EF25C567Q34497715-C3BC9E74-8ADA-4720-944F-52616BB9C54FQ34506218-03F7FA38-1F5E-4785-A9E2-492A0A015FA3Q36314101-A3095598-9C06-457B-8E02-C4F29B46585DQ36499690-A9C5A428-DDFC-4C76-8303-9447197D43BEQ37456507-4BB166E2-EE6B-4F87-9C51-A1D052942078Q38466939-AA760315-CE83-402B-8F96-67A3F86A5E68Q41986288-FB2BCD50-5FC5-4787-BC61-8C603487BEFEQ51364278-20C3C210-9614-410F-B3B3-9317A132A632Q53091375-80C13B29-B5AC-4065-BC3D-6B3AB6C94FA9Q53885801-E5914CD6-8A96-4891-8FD4-AC9DED8BF5D5
P2860
Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Managing the progression of lo ...... c options for the man at risk.
@en
type
label
Managing the progression of lo ...... c options for the man at risk.
@en
prefLabel
Managing the progression of lo ...... c options for the man at risk.
@en
P2093
P2860
P1433
P1476
Managing the progression of lo ...... c options for the man at risk.
@en
P2093
Marc Gittelman
Moon-Kee Chung
Norman Zinner
Stephan Madersbacher
P2860
P304
P356
10.1111/J.1464-410X.2007.07056.X
P577
2007-08-01T00:00:00Z